202 related articles for article (PubMed ID: 19029942)
1. Human papillomaviruses, cervical cancer and cell polarity.
Thomas M; Narayan N; Pim D; Tomaić V; Massimi P; Nagasaka K; Kranjec C; Gammoh N; Banks L
Oncogene; 2008 Nov; 27(55):7018-30. PubMed ID: 19029942
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins.
Yugawa T; Kiyono T
Rev Med Virol; 2009 Mar; 19(2):97-113. PubMed ID: 19156753
[TBL] [Abstract][Full Text] [Related]
3. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
[TBL] [Abstract][Full Text] [Related]
4. Human papillomaviruses and the specificity of PDZ domain targeting.
Pim D; Bergant M; Boon SS; Ganti K; Kranjec C; Massimi P; Subbaiah VK; Thomas M; Tomaić V; Banks L
FEBS J; 2012 Oct; 279(19):3530-3537. PubMed ID: 22805590
[TBL] [Abstract][Full Text] [Related]
5. Human and primate tumour viruses use PDZ binding as an evolutionarily conserved mechanism of targeting cell polarity regulators.
Tomaić V; Gardiol D; Massimi P; Ozbun M; Myers M; Banks L
Oncogene; 2009 Jan; 28(1):1-8. PubMed ID: 18820705
[TBL] [Abstract][Full Text] [Related]
6. The high-risk HPV E6 oncoprotein preferentially targets phosphorylated nuclear forms of hDlg.
Narayan N; Subbaiah VK; Banks L
Virology; 2009 Apr; 387(1):1-4. PubMed ID: 19307009
[TBL] [Abstract][Full Text] [Related]
7. Genetic diversity of human papillomavirus type 16 E6, E7, and L1 genes in Italian women with different grades of cervical lesions.
Cento V; Ciccozzi M; Ronga L; Perno CF; Ciotti M
J Med Virol; 2009 Sep; 81(9):1627-34. PubMed ID: 19626616
[TBL] [Abstract][Full Text] [Related]
8. Estrogens and human papilloma virus oncogenes regulate human ether-à-go-go-1 potassium channel expression.
Díaz L; Ceja-Ochoa I; Restrepo-Angulo I; Larrea F; Avila-Chávez E; García-Becerra R; Borja-Cacho E; Barrera D; Ahumada E; Gariglio P; Alvarez-Rios E; Ocadiz-Delgado R; Garcia-Villa E; Hernández-Gallegos E; Camacho-Arroyo I; Morales A; Ordaz-Rosado D; García-Latorre E; Escamilla J; Sánchez-Peña LC; Saqui-Salces M; Gamboa-Dominguez A; Vera E; Uribe-Ramírez M; Murbartián J; Ortiz CS; Rivera-Guevara C; De Vizcaya-Ruiz A; Camacho J
Cancer Res; 2009 Apr; 69(8):3300-7. PubMed ID: 19351862
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells.
Rincon-Orozco B; Halec G; Rosenberger S; Muschik D; Nindl I; Bachmann A; Ritter TM; Dondog B; Ly R; Bosch FX; Zawatzky R; Rösl F
Cancer Res; 2009 Nov; 69(22):8718-25. PubMed ID: 19887612
[TBL] [Abstract][Full Text] [Related]
10. PDZ domains and viral infection: versatile potentials of HPV-PDZ interactions in relation to malignancy.
Nagasaka K; Kawana K; Osuga Y; Fujii T
Biomed Res Int; 2013; 2013():369712. PubMed ID: 24093094
[TBL] [Abstract][Full Text] [Related]
11. Expression of CPEB, GAPDH and U6snRNA in cervical and ovarian tissue during cancer development.
Hansen CN; Ketabi Z; Rosenstierne MW; Palle C; Boesen HC; Norrild B
APMIS; 2009 Jan; 117(1):53-9. PubMed ID: 19161537
[TBL] [Abstract][Full Text] [Related]
12. Involvement of human papillomavirus infections in prostate cancer progression.
Al Moustafa AE
Med Hypotheses; 2008 Aug; 71(2):209-11. PubMed ID: 18468811
[TBL] [Abstract][Full Text] [Related]
13. Structural insights into a wildtype domain of the oncoprotein E6 and its interaction with a PDZ domain.
Mischo A; Ohlenschläger O; Hortschansky P; Ramachandran R; Görlach M
PLoS One; 2013; 8(4):e62584. PubMed ID: 23638119
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling in cervical cancer: identification of novel markers for disease diagnosis and therapy.
Martin CM; Astbury K; McEvoy L; O'Toole S; Sheils O; O'Leary JJ
Methods Mol Biol; 2009; 511():333-59. PubMed ID: 19347305
[TBL] [Abstract][Full Text] [Related]
15. NucliSENS EasyQ HPV v1 test - Testing for oncogenic activity of human papillomaviruses.
Jeantet D; Schwarzmann F; Tromp J; Melchers WJ; van der Wurff AA; Oosterlaken T; Jacobs M; Troesch A
J Clin Virol; 2009 Jul; 45 Suppl 1():S29-37. PubMed ID: 19651366
[TBL] [Abstract][Full Text] [Related]
16. The Human Papillomavirus E6 PDZ Binding Motif: From Life Cycle to Malignancy.
Ganti K; Broniarczyk J; Manoubi W; Massimi P; Mittal S; Pim D; Szalmas A; Thatte J; Thomas M; Tomaić V; Banks L
Viruses; 2015 Jul; 7(7):3530-51. PubMed ID: 26147797
[TBL] [Abstract][Full Text] [Related]
17. HPV E6 oncoprotein as a potential therapeutic target in HPV related cancers.
Manzo-Merino J; Thomas M; Fuentes-Gonzalez AM; Lizano M; Banks L
Expert Opin Ther Targets; 2013 Nov; 17(11):1357-68. PubMed ID: 24094136
[TBL] [Abstract][Full Text] [Related]
18. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells.
Rampias T; Sasaki C; Weinberger P; Psyrri A
J Natl Cancer Inst; 2009 Mar; 101(6):412-23. PubMed ID: 19276448
[TBL] [Abstract][Full Text] [Related]
19. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
20. The pro-angiogenic factors stimulated by human papillomavirus type 16 E6 and E7 protein in C33A and human fibroblasts.
Xi L; Wang S; Wang C; Xu Q; Li P; Tian X; Wu P; Wang W; Deng D; Zhou J; Ma D
Oncol Rep; 2009 Jan; 21(1):25-31. PubMed ID: 19082439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
